Inflammatory Bowel Disease Outcomes Following Fecal Microbiota Transplantation for Recurrent C. difficile Infection
dc.contributor.author | Allegretti, Jessica R. | |
dc.contributor.author | Kelly, Colleen R. | |
dc.contributor.author | Grinspan, Ari | |
dc.contributor.author | Mullish, Benjamin H. | |
dc.contributor.author | Hurtado, Jonathan | |
dc.contributor.author | Carrellas, Madeline | |
dc.contributor.author | Marcus, Jenna | |
dc.contributor.author | Marchesi, Julian R. | |
dc.contributor.author | McDonald, Julie A.K. | |
dc.contributor.author | Gerardin, Ylaine | |
dc.contributor.author | Silverstein, Michael | |
dc.contributor.author | Pechlivanis, Alexandros | |
dc.contributor.author | Barker, Grace F. | |
dc.contributor.author | Blanco, Jesus Miguens | |
dc.contributor.author | Alexander, James L. | |
dc.contributor.author | Gallagher, Kate I. | |
dc.contributor.author | Pettee, Will | |
dc.contributor.author | Phelps, Emmalee | |
dc.contributor.author | Nemes, Sara | |
dc.contributor.author | Sagi, Sashidhar V. | |
dc.contributor.author | Bohm, Matthew | |
dc.contributor.author | Kassam, Zain | |
dc.contributor.author | Fischer, Monika | |
dc.contributor.department | Medicine, School of Medicine | en_US |
dc.date.accessioned | 2023-04-06T15:24:23Z | |
dc.date.available | 2023-04-06T15:24:23Z | |
dc.date.issued | 2021-08-19 | |
dc.description.abstract | Background: Recurrent Clostridioides difficile infection (CDI) in patients with inflammatory bowel disease (IBD) is a clinical challenge. Fecal microbiota transplantation (FMT) has emerged as a recurrent CDI therapy. Anecdotal concerns exist regarding worsening of IBD activity; however, prospective data among IBD patients are limited. Methods: Secondary analysis from an open-label, prospective, multicenter cohort study among IBD patients with 2 or more CDI episodes was performed. Participants underwent a single FMT by colonoscopy (250 mL, healthy universal donor). Secondary IBD-related outcomes included rate of de novo IBD flares, worsening IBD, and IBD improvement-all based on Mayo or Harvey-Bradshaw index (HBI) scores. Stool samples were collected for microbiome and targeted metabolomic profiling. Results: Fifty patients enrolled in the study, among which 15 had Crohn's disease (mean HBI, 5.8 ± 3.4) and 35 had ulcerative colitis (mean partial Mayo score, 4.2 ± 2.1). Overall, 49 patients received treatment. Among the Crohn's disease cohort, 73.3% (11 of 15) had IBD improvement, and 4 (26.6%) had no disease activity change. Among the ulcerative colitis cohort, 62% (22 of 34) had IBD improvement, 29.4% (11 of 34) had no change, and 4% (1 of 34) experienced a de novo flare. Alpha diversity significantly increased post-FMT, and ulcerative colitis patients became more similar to the donor than Crohn's disease patients (P = 0.04). Conclusion: This prospective trial assessing FMT in IBD-CDI patients suggests IBD outcomes are better than reported in retrospective studies. | en_US |
dc.eprint.version | Final published version | en_US |
dc.identifier.citation | Allegretti JR, Kelly CR, Grinspan A, et al. Inflammatory Bowel Disease Outcomes Following Fecal Microbiota Transplantation for Recurrent C. difficile Infection. Inflamm Bowel Dis. 2021;27(9):1371-1378. doi:10.1093/ibd/izaa283 | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/32262 | |
dc.language.iso | en_US | en_US |
dc.publisher | Oxford University Press | en_US |
dc.relation.isversionof | 10.1093/ibd/izaa283 | en_US |
dc.relation.journal | Inflammatory Bowel Diseases | en_US |
dc.rights | Publisher Policy | en_US |
dc.source | PMC | en_US |
dc.subject | Clostridioides difficile infection | en_US |
dc.subject | Crohn’s disease | en_US |
dc.subject | Butyrate | en_US |
dc.subject | Fecal microbiota transplantation | en_US |
dc.subject | Inflammatory bowel disease | en_US |
dc.subject | Microbiome | en_US |
dc.subject | Ulcerative colitis | en_US |
dc.title | Inflammatory Bowel Disease Outcomes Following Fecal Microbiota Transplantation for Recurrent C. difficile Infection | en_US |
dc.type | Article | en_US |
ul.alternative.fulltext | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8376126/ | en_US |